



# Press Release

**FOR IMMEDIATE RELEASE**

## **CRITICAL OUTCOME TECHNOLOGIES INC. ANNOUNCES PROPOSAL RECEIVED FROM DDP THERAPEUTICS**

**London, Ontario (June 26, 2007): Critical Outcome Technologies Inc. (TSX Venture: COT)**, announced today that it received a proposal from 6441513 Canada Inc. operating as DDP Therapeutics (DDP), a Canadian private corporation, for the purchase by Critical Outcome Technologies Inc. (COTI) of the 90% share ownership of DDP not currently owned by COTI.

DDP was formed in 2005 to develop a library of small cell lung cancer (SCLC) molecules discovered by COTI using its CHEMSAS® technology.

A Special Committee of the Board consisting of independent Directors was created to review the proposal. The committee recommended, based on recent positive preclinical test results of the SCLC molecules related to toxicity and resistance, along with preliminary mechanism of action data, that further investigation and evaluation of the proposal was warranted. The Company has begun its due diligence process.

### **About Critical Outcome Technologies Inc. (COTI)**

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For further information, please visit the website at [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

Michael Barr, Director of Business Development and Marketing  
519-858-5157  
[mbarr@criticaloutcome.com](mailto:mbarr@criticaloutcome.com)

*The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.*